Market Introduction

Sleep apnea is a condition where breathing is interrupted during sleep. It is considered a serious sleep disorder in which breathing repeatedly stops and starts. These breathing interruptions can cause lower quality of sleep and can affect the body's supply of oxygen, which may lead to serious health consequences. The sleep apnea can be classified into three types namely obstructive sleep apnea, central sleep apnea and complex/mixed sleep apnea. The obstructive sleep apnea is the most common type of sleep apnea and occurs when the airway at the back of the throat becomes physically blocked. In central sleep apnea, brain fails to send proper signals to the muscles that control breathing. Whereas, complex/mixed sleep apnea is the condition where the patient has both obstructive sleep apnea and central sleep apnea. Sleep apnea devices are utilized for the diagnosis and treatment of the condition.

Market - Headwinds & Tailwinds

The global sleep apnea devices market is mainly driven by growing prevalence of sleep apnea, technological advancements, rising awareness about the complications related to untreated sleep apnea, favorable reimbursement policies and adoption of sleep telehealth. Furthermore, growing demand for home healthcare is also playing a pivotal role in contributing to the growth of the market globally. However, lack of patient compliance, complications related to device usage and complex referral pathways and long waiting period acts as a deterrent for effective diagnosis and treatment of sleep apnea.

Market Segmentation & Insights

The global sleep apnea devices market has been analyzed from three main segments: Product, End User and Region.

Sleep Apnea Devices Market, By Product

Based on product, the sleep apnea devices market has been segmented into therapeutic devices, diagnostic devices and other devices. The therapeutic devices are further categorized into PAP devices, facial interfaces, adaptive servo-ventilation instruments, accessories and oral appliances. Whereas, the diagnostic devices segment is further categorized into polysomnography devices (PSG), home sleep screening devices, oximeters, actigraphy systems and sleep screening devices. The therapeutic devices segment holds the largest share in the market. The growth of the segment can be attributed to increasing pool of diagnosed sleep apnea patients, improving reimbursement scenario for these devices and continuous innovations in therapeutic devices which allows long-term adherence thereby improving patient management.

Sleep Apnea Devices Market by End User

Based on end user, the sleep apnea devices market has been segmented into hospitals & sleep laboratories and home care settings. The home care settings segment is expected to be the fastest growing segment in the market during the forecast period. The growth of the segment can be attributed to increasing focus on telehealth and growing demand for home healthcare during COVID-19 pandemic owing to shut down of sleep clinics amidst lockdown restrictions.

Sleep Apnea Devices Market by Region

Based on region, the global sleep apnea devices market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominated the sleep apnea devices market, followed by Asia Pacific. The large share of North America in the global market can be attributed to shift in trend towards home sleep testing in the U.S., efforts to increase awareness regarding sleep apnea by private institutions and governments in the U.S. and Canada, developed healthcare infrastructure, rising prevalence of sleep apnea, presence of key prominent players, rising investments and favorable reimbursement policies.

Competitive Landscape

The sleep apnea devices market is marked by presence of prominent players such as Koninklijke Philips N.V., ResMed, Fisher & Paykel Healthcare Limited., SomnoMed, At Whole You, Braebon Medical Corporation, Compumedics Limited, BMC Medical Co., Ltd., Itamar Medical Ltd., DeVilbiss Healthcare LLC, among others.

Snapshot: Industry Developments

• In Jun 2021, LivaNova PLC announced that it has received approval from the U.S. FDA to proceed with its investigational device exemption (IDE) clinical study, "Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation (OSPREY)." The OSPREY study will seek to demonstrate the safety and effectiveness of the aura6000 System, the LivaNova implantable hypoglossal neurostimulator intended to treat adult patients with moderate to severe obstructive sleep apnea (OSA)

• In Apr 2021, ZOLL Medical Corporation acquired Respicardia Inc., a maker of implantable neurostimulators to treat moderate to severe central sleep apnea (CSA). The acquisition was aimed to combine ZOLL expertise in cardiac and respiratory care with Respicardia's novel remed? System to make a meaningful difference in the health and quality of life for many patients

• In Mar 2021, Philips, announced partnership with the Middle East's Saudi German Health (SGH) Group to provide solutions aimed at treating and/or alleviating the symptoms of sleep disorders in the Kingdom of Saudi Arabia (KSA)

• In Feb 2021, GoPAPfree, announced the launch of their new product O2Vent Optima, a highly effective and more convenient alternative to CPAP therapy

• In Oct 2020, Acurable announced the availability of its first product, AcuPebble SA100, a small wearable device which enables a fully automated and remote diagnosis of obstructive sleep apnoea (OSA)

• In Sept 2020, Somnera announced the U.S. launch of the Somnera System for Sleep Apnea patients

• In Dec 2019, Itamar Medical Ltd. and SoClean Inc., announced collaboration agreement between their respective wholly owned subsidiaries to make Itamar Medical's WatchPAT ONE home sleep apnea test and Digital Health Services available through direct-to-consumer channels

• In Oct 2019, Medline and Bleep LLC., entered into partnership to co-brand and distribute the DreamPort Sleep Solution, the smallest and lightest CPAP mask-solution in the world, to the hospital and post-acute care markets

• In Sept 2019, Royal Philips announced the commercial launch of Philips NightBalance, a prescription sleep position therapy device designed for patients with positional obstructive sleep apnea (OSA)

Key Insights Captured in the Report

• Quantitative (market size and forecasts) and qualitative insights of the market across years - historical years, current year and forecasted years

• Deep-rooted insights on headwinds, tailwinds and opportunities prevailing in the market

• Quantitative (market size and forecasts) and qualitative insights at segment and sub-segment level

• Comprehensive quantitative (market size and forecasts) and qualitative insights on geographic, regional and country level markets

• Granular insights on the competitive landscape prevailing in the market

• Competitive mapping of strategic developments